Cover Image
市場調查報告書

Myc前致癌基因蛋白質 (前致癌基因c-Myc,E類鹼性螺旋-環-螺旋 (bHLH) 蛋白質39) - 開發中產品分析

Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 358698
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
Myc前致癌基因蛋白質 (前致癌基因c-Myc,E類鹼性螺旋-環-螺旋 (bHLH) 蛋白質39) - 開發中產品分析 Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Review, H1 2016
出版日期: 2016年04月30日 內容資訊: 英文 45 Pages
簡介

Myc (c-Myc) 是Myc遺傳基因──亦即是轉錄因子藉由編碼的調節遺傳基因而編碼的蛋白質,可介入細胞週期的進行、細胞凋亡、細胞性狀轉換。

本報告提供Myc前致癌基因蛋白質 (前致癌基因c-Myc,E類鹼性螺旋-環-螺旋 (bHLH) 蛋白質39)的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Dicerna Pharmaceuticals, Inc.
  • Phylogica Limited
  • Sorrento Therapeutics, Inc.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

目錄
Product Code: GMDHC0018TDB

Summary

Global Markets Direct's, 'Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Review, H1 2016', provides in depth analysis on Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted pipeline therapeutics.

The report provides comprehensive information on the Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39)
  • The report reviews Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) Overview
  • Therapeutics Development
    • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Stage of Development
    • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Therapy Area
    • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Indication
  • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Companies
  • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Products under Development by Universities/Institutes
  • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Companies Involved in Therapeutics Development
    • Dicerna Pharmaceuticals, Inc.
    • Phylogica Limited
    • Sorrento Therapeutics, Inc.
  • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Drug Profiles
    • DCRM-1711 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JY-3094 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit c-Myc and mTOR for Chondrosarcoma and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target c-Myc for Multiple Myeloma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit c-Myc for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit c-Myc for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit c-Myc for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Dormant Projects
  • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Discontinued Products
  • Myc Proto-Oncogene Protein (Proto-Oncogene c-Myc or Class E Basic Helix-Loop-Helix Protein 39) - Featured News & Press Releases
    • Dec 21, 2015: Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors
    • Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer
    • Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer
    • Jun 01, 2015: Dicerna Presents Preliminary Safety and Efficacy Data from DCR-MYC Phase 1 Study in Patients with Advanced Solid Tumors at the 2015 ASCO Annual Meeting
    • May 14, 2015: Dicerna Announces Expansion of Ongoing DCR-MYC Phase 1 Study to Evaluate Safety and Efficacy in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNETs)
    • May 13, 2015: Dicerna to Present Interim Clinical Data from First DCR-MYC Phase 1 Study in Patients with Advanced Solid Tumors at the 2015 ASCO Annual Meeting
    • Feb 02, 2015: Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma
    • Apr 16, 2014: Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in Patients with Solid Tumors and Hematological Malignancies
    • Apr 02, 2013: Dicerna Pharma Announces First Patent Grant In Japan To Dicer Substrate siRNA Molecules
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
  • Pipeline by Phylogica Limited, H1 2016
  • Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top